Eloxx Pharmaceuticals, Inc.

ELOX

Healthcare|Biotechnology|US

$12.44

-0.36 (-2.81%)

DCF Value

$1.22

Tangible Book / Share

$6.84

Cash / Share

$9.13

Clinical Trials (9)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07523581 EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety	Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive	P2	Recruiting	24	RCT, Double-blind	Exaluren
NCT04126473 A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele	Cystic Fibrosis	P2	Completed	17	Open-label	ELX-02, Ivacaftor
NCT04135495 A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele	Cystic Fibrosis	P2	Completed	17	Open-label	ELX-02, Ivacaftor
NCT05448755 A Study of ELX-02 in Patients With Alport Syndrome	Alport Syndrome	P2	Completed	3	Open-label	ELX-02
NCT04069260 A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis	Genetic Disease, Nonsense Mutation	P2	Terminated	3	Open-label	ELX-02
NCT03776539 A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02	Impaired Renal Function	P1	Completed	24	Open-label	ELX-02
NCT03292302 Phase 1 Study of ELX-02 in Healthy Adults	Genetic Disease, Nonsense Mutation	P1	Completed	18	RCT, Double-blind	Placebo, ELX-02
NCT02807961 Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers	Genetic Diseases, Nonsense Mutations	P1	Terminated	42	RCT, Double-blind	ELX-02, Placebo
NCT03309605 Phase 1 Study of ELX-02 in Healthy Adult Subjects	Genetic Disease, Nonsense Mutation	P1	Completed	62	RCT, Double-blind	ELX-02, Placebo